Table Info

Table 1.

Experimental T-cell-based immunotherapies tested in pre-clinical models of Parkinson’s disease

Treatment	Effect on T-cells	Effect on Parkinson’s disease	Model	Reference
FK506	Inhibits T-cell activation	Attenuates motor impairment and neurodegeneration	AAV-A53T-hαSyn in rat	[22]
FTY720	Arrest T-cells in lymph nodes	Attenuates neuroinflammation	AAV-hαSyn in mouse	[17]
FTY720	Arrest T-cells in lymph nodes	Attenuates motor impairment, neuroinflammation and neurodegeneration	6-OHDA in mouse	[55]
FTY720	Arrest T-cells in lymph nodes	Attenuates motor impairment and neurodegeneration	6-OHDA in mouse	[56]
FTY720	Arrest T-cells in lymph nodes	Attenuates motor impairment and neurodegeneration	Rotenone in mouse	[56]
FTY720	Arrest T-cells in lymph nodes	Attenuates motor impairment and neurodegeneration	MPTP in mouse	[57]
Rapamicyn + αSyn	Increases Treg differentiation	Attenuates neuroinflammation, neurodegeneration and synuclein pathology	Transgenic mice overexpressing hαSyn	[58]
PNU-282987	Increases Treg response	Attenuates motor impairment, neuroinflammation and neurodegeneration	6-OHDA in rat	[59]
VIP	Increases Treg number and activity	Attenuates neuroinflammation and neurodegeneration	MPTP in mouse	[11]
VIP (LBT-3627)	Increases Treg number and activity	Attenuates neuroinflammation and neurodegeneration	AAV-hαSyn in rat	[64]
VIP (LBT-3627)	Increases Treg number and activity	Attenuates neuroinflammation and neurodegeneration	6-OHDA in rat	[64]
VIP (LBT-3627)	Increases Treg number and activity	Attenuates neuroinflammation and neurodegeneration	MPTP in mouse	[65]
GM-CSF	Favours Treg generation	Attenuates neuroinflammation and neurodegeneration	MPTP in mouse	[69]
GM-CSF	Favours Treg generation	Attenuates neuroinflammation and neurodegeneration	AAV-hαSyn in rat	[69]
PG01037	Inhibits Th1/Th17 and increases Treg activity	Attenuates motor impairment, neuroinflammation and neurodegeneration	MPTP in mouse	[75]
PG01037	Inhibits Th1/Th17 and increases Treg activity	Attenuates neurodegeneration	6-OHDA in mouse	[75]
Grp94 + αSyn	Promotes Treg and Th1 response	Attenuates neuroinflammation	MPTP in mouse	[76]

Declarations

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Programa de Apoyo a Centros con Financiamiento Basal [AFB-170004] from “Comisión Nacional de Investigación Científica y Tecnológica de Chile (CONICYT)”, by grants [FONDECYT-1210013] from “Fondo Nacional de Desarrollo Científico y Tecnológico de Chile”, and [MJFF-15076] from the Michael J. Fox Foundation for Parkinson’s research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. [DOI] [PubMed]

Lim KL, Zhang CW. Molecular events underlying Parkinson’s disease - an interwoven tapestry. Front Neurol. 2013;4:33. [DOI] [PubMed] [PMC]

González H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation. 2014;11:201. [DOI] [PubMed] [PMC]

Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562. [DOI] [PubMed] [PMC]

Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep. 2013;3:1393. [DOI] [PubMed] [PMC]

González H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol. 2014;274:1–13. [DOI] [PubMed]

Campos-Acuña J, Elgueta D, Pacheco R. T-cell-driven inflammation as a mediator of the gut-brain axis involved in Parkinson’s disease. Front Immunol. 2019;10:239. [DOI] [PubMed] [PMC]

Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev. 1987;98:95–114. [DOI] [PubMed]

Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546:656–61. [DOI] [PubMed] [PMC]

10.

Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, et al. Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3:e1376. [DOI] [PubMed] [PMC]

11.

Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184:2261–71. [DOI] [PubMed] [PMC]

12.

González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al. Dopamine receptor D3 expressed on CD4⁺ T cells favors neurodegeneration of dopaminergic neurons during Parkinson’s disease. J Immunol. 2013;190:5048–56. [DOI] [PubMed]

13.

Theodore S, Maragos W. 6-hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson’s disease. Immunopharmacol Immunotoxicol. 2015; 37:393–9. [DOI] [PubMed]

14.

Ambrosi G, Kustrimovic N, Siani F, Rasini E, Cerri S, Ghezzi C, et al. Complex changes in the innate and adaptive immunity accompany progressive degeneration of the nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine in the rat. Neurotox Res. 2017;32:71–81. [DOI] [PubMed]

15.

Iba M, Kim C, Sallin M, Kwon S, Verma A, Overk C, et al. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models. J Neuroinflammation. 2020;17:214. [DOI] [PubMed] [PMC]

16.

Sommer A, Fadler T, Dorfmeister E, Hoffmann AC, Xiang W, Winner B, et al. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation. 2016;13:174. [DOI] [PubMed] [PMC]

17.

Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson disease. Brain. 2021;144:2047–59. [DOI] [PubMed] [PMC]

18.

Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008;67:1149–58. [DOI] [PubMed] [PMC]

19.

Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72:624–45. [DOI] [PubMed]

20.

Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of α-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One. 2010;5:e8784. [DOI] [PubMed] [PMC]

21.

Subbarayan MS, Hudson C, Moss LD, Nash KR, Bickford PC. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson’s disease. J Neuroinflammation. 2020;17:242. [DOI] [PubMed] [PMC]

22.

Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson’s disease. Neurobiol Aging. 2015;36:1559–68. [DOI] [PubMed]

23.

Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4⁺ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182–92. [DOI] [PubMed] [PMC]

24.

Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun. 2020;11:1875. [DOI] [PubMed] [PMC]

25.

Wang BY, Ye YY, Qian C, Zhang HB, Mao HX, Yao LP, et al. Stress increases MHC-I expression in dopaminergic neurons and induces autoimmune activation in Parkinson’s disease. Neural Regen Res. 2021;16:2521–7. [DOI] [PubMed] [PMC]

26.

Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1^–/– mice. Nature. 2019;571:565–9. [DOI] [PubMed]

27.

Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633. [DOI] [PubMed] [PMC]

28.

Galiano-Landeira J, Torra A, Vila M, Bové J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson’s disease. Brain. 2020;143:3717–33. [DOI] [PubMed]

29.

George S, Tyson T, Rey NL, Sheridan R, Peelaerts W, Becker K, et al. T cells limit accumulation of aggregate pathology following intrastriatal injection of α-synuclein fibrils. J Parkinsons Dis. 2021;11:585–603. [DOI] [PubMed] [PMC]

30.

Ip CW, Beck SK, Volkmann J. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson’s disease. J Neural Transm (Vienna). 2015;122:1633–43. [DOI] [PubMed]

31.

Christiansen JR, Olesen MN, Otzen DE, Romero-Ramos M, Sanchez-Guajardo V. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. J Neuroinflammation. 2016;13:74. [DOI] [PubMed] [PMC]

32.

Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N. Vaccine adjuvants – current status and prospects on controlled release adjuvancity. Saudi Pharm J. 2011;19:197–206. [DOI] [PubMed] [PMC]

33.

Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J. The class II molecules of the human and murine major histocompatibility complex. Cell. 1984;36:1–13. [DOI] [PubMed]

34.

Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63:325–35. [DOI] [PubMed] [PMC]

35.

Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 2000; 290:985–9. [DOI] [PubMed]

36.

Yu Z, Xu X, Xiang Z, Zhou J, Zhang Z, Hu C, et al. Nitrated α-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One. 2010;5:e9956. [DOI] [PubMed] [PMC]

37.

González H, Contreras F, Pacheco R. Regulation of the neurodegenerative process associated to Parkinson’s disease by CD4+ T-cells. J Neuroimmune Pharmacol. 2015;10:561–75. [DOI] [PubMed]

38.

Davtyan H, Zagorski K, Petrushina I, Kazarian K, Goldberg NRS, Petrosyan J, et al. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging. 2017;59:156–70. [DOI] [PubMed] [PMC]

39.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160–4. [DOI] [PubMed]

40.

Singhania A, Pham J, Dhanwani R, Frazier A, Rezende Dutra J, Marder KS, et al. The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse. Sci Rep. 2021;11:302. [DOI] [PubMed] [PMC]

41.

Bemporad F, Chiti F. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol. 2012;19:315–27. [DOI] [PubMed]

42.

Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol. 2014;15:384–96. [DOI] [PubMed]

43.

Hartl FU. Protein misfolding diseases. Annu Rev Biochem. 2017;86:21–6. [DOI] [PubMed]

44.

Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469–78. [DOI] [PubMed]

45.

Moyano DF, Goldsmith M, Solfiell DJ, Landesman-Milo D, Miranda OR, Peer D, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134:3965–7. [DOI] [PubMed] [PMC]

46.

Zottig X, Côté-Cyr M, Arpin D, Archambault D, Bourgault S. Protein supramolecular structures: from self-assembly to nanovaccine design. Nanomaterials (Basel). 2020;10:1008. [DOI]

47.

Leal-Lasarte M, Mannini B, Chiti F, Vendruscolo M, Dobson CM, Roodveldt C, et al. Distinct responses of human peripheral blood cells to different misfolded protein oligomers. Immunology. 2021;164:358–71. [DOI] [PubMed] [PMC]

48.

Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010;6:140–7. [DOI] [PubMed]

49.

Caggiu E, Paulus K, Arru G, Piredda R, Sechi GP, Sechi LA. Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson’s disease, a triggering role in the disease? J Neuroimmunol. 2016;291:110–4. [DOI] [PubMed]

50.

Caggiu E, Paulus K, Galleri G, Arru G, Manetti R, Sechi GP, et al. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson’s disease. J Neuroimmunol. 2017;310:26–31. [DOI] [PubMed]

51.

Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry. 1992;31:3896–901. [DOI] [PubMed]

52.

Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807–15. [DOI] [PubMed]

53.

Kitamura Y, Itano Y, Kubo T, Nomura Y. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol. 1994;50:221–4. [DOI] [PubMed]

54.

Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, et al. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients. CNS Neurosci Ther. 2018;24:1175–84. [DOI] [PubMed] [PMC]

55.

Ren M, Han M, Wei X, Guo Y, Shi H, Zhang X, et al. FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models. Neurochem Res. 2017;42:686–96. [DOI] [PubMed]

56.

Zhao P, Yang X, Yang L, Li M, Wood K, Liu Q, et al. Neuroprotective effects of fingolimod in mouse models of Parkinson’s disease. FASEB J. 2017;31:172–9. [DOI] [PubMed]

57.

Motyl J, Przykaza Ł, Boguszewski PM, Kosson P, Strosznajder JB. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson’s disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology. 2018;135:139–50. [DOI] [PubMed]

58.

Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, et al. Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies. J Neurosci. 2018;38:1000–14. [DOI] [PubMed] [PMC]

59.

Jiang Y, Ma H, Wang X, Wang Z, Yang Y, Li L, et al. Protective effect of the α7 nicotinic receptor agonist PNU-282987 on dopaminergic neurons against 6-hydroxydopamine, regulating anti-neuroinflammatory and the immune balance pathways in rat. Front Aging Neurosci. 2021;12:606927. [DOI] [PubMed] [PMC]

60.

Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Vasoactive intestinal peptide generates CD4⁺CD25⁺ regulatory T cells in vivo. J Leukoc Biol. 2005;78:1327–38. [DOI] [PubMed]

61.

Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol. 2006;36:318–26. [DOI] [PubMed]

62.

Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A. 2005;102:13562–7. [DOI] [PubMed] [PMC]

63.

Varela N, Chorny A, Gonzalez-Rey E, Delgado M. Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin Biol Ther. 2007;7:461–78. [DOI] [PubMed]

64.

Mosley RL, Lu Y, Olson KE, Machhi J, Yan W, Namminga KL, et al. A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson’s disease. Front Cell Neurosci. 2019;13:421. [DOI] [PubMed] [PMC]

65.

Olson KE, Kosloski-Bilek LM, Anderson KM, Diggs BJ, Clark BE, Gledhill JM Jr, et al. Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice. J Neurosci. 2015;35:16463–78. [DOI] [PubMed] [PMC]

66.

Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res. 2015;35:585–99. [DOI] [PubMed] [PMC]

67.

Schutt CR, Gendelman HE, Mosley RL. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease. Mol Neurodegener. 2018;13:26. [DOI] [PubMed] [PMC]

68.

Lotfi N, Thome R, Rezaei N, Zhang GX, Rezaei A, Rostami A, et al. Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol. 2019;10:1265. [DOI] [PubMed] [PMC]

69.

Olson KE, Namminga KL, Lu Y, Thurston MJ, Schwab AD, de Picciotto S, et al. Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson’s disease. Biomaterials. 2021;272:120786. [DOI] [PubMed] [PMC]

70.

Pacheco R. Targeting dopamine receptor D3 signalling in inflammation. Oncotarget. 2017;8:7224–5. [DOI] [PubMed] [PMC]

71.

Contreras F, Prado C, González H, Franz D, Osorio-Barrios F, Osorio F, et al. Dopamine receptor D3 signaling on CD4⁺ T cells favors Th1- and Th17-mediated immunity. J Immunol. 2016;196:4143–9. [DOI] [PubMed]

72.

Ugalde V, Contreras F, Prado C, Chovar O, Espinoza A, Pacheco R. Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation. Mucosal Immunol. 2021;14:652–66. [DOI] [PubMed]

73.

Elgueta D, Contreras F, Prado C, Montoya A, Ugalde V, Chovar O, et al. Dopamine receptor D3 expression is altered in CD4⁺ T-cells from Parkinson’s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front Immunol. 2019;10:981. [DOI] [PubMed] [PMC]

74.

Montoya A, Elgueta D, Campos J, Chovar O, Falcón P, Matus S, et al. Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J Neuroinflammation. 2019;16:258. [DOI] [PubMed] [PMC]

75.

Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, et al. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson’s disease. Neuropharmacology. 2017;113:110–23. [DOI] [PubMed]

76.

Villadiego J, Labrador-Garrido A, Franco JM, Leal-Lasarte M, De Genst EJ, Dobson CM, et al. Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia. 2018;66:191–205. [DOI] [PubMed]